- Home
- MOBX vs APLT Comparison
MOBX vs APLT Comparison
Compare MOBX & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOBX
- APLT
- Stock Information
- Founded
- MOBX 2020
- APLT 2016
- Country
- MOBX United States
- APLT United States
- Employees
- MOBX N/A
- APLT N/A
- Industry
- MOBX
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- MOBX
- APLT Health Care
- Exchange
- MOBX Nasdaq
- APLT Nasdaq
- Market Cap
- MOBX 57.1M
- APLT 63.6M
- IPO Year
- MOBX N/A
- APLT 2019
- Fundamental
- Price
- MOBX $0.93
- APLT $0.42
- Analyst Decision
- MOBX
- APLT Buy
- Analyst Count
- MOBX 0
- APLT 6
- Target Price
- MOBX N/A
- APLT $6.10
- AVG Volume (30 Days)
- MOBX 1.7M
- APLT 883.6K
- Earning Date
- MOBX 08-13-2025
- APLT 11-06-2025
- Dividend Yield
- MOBX N/A
- APLT N/A
- EPS Growth
- MOBX N/A
- APLT N/A
- EPS
- MOBX N/A
- APLT N/A
- Revenue
- MOBX $10,984,000.00
- APLT $121,000.00
- Revenue This Year
- MOBX N/A
- APLT N/A
- Revenue Next Year
- MOBX N/A
- APLT $5,931.24
- P/E Ratio
- MOBX N/A
- APLT N/A
- Revenue Growth
- MOBX 180.13
- APLT N/A
- 52 Week Low
- MOBX $0.55
- APLT $0.30
- 52 Week High
- MOBX $2.47
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- MOBX 45.49
- APLT 38.92
- Support Level
- MOBX $1.00
- APLT $0.43
- Resistance Level
- MOBX $1.19
- APLT $0.46
- Average True Range (ATR)
- MOBX 0.16
- APLT 0.03
- MACD
- MOBX -0.01
- APLT -0.01
- Stochastic Oscillator
- MOBX 14.17
- APLT 0.35
About MOBX Mobix Labs Inc.
Mobix Labs Inc. specializes in designing, developing, and selling components and systems for wireless and wired connectivity, radio frequency (RF) technologies, switching, and electromagnetic interference (EMI) filtering solutions. The company serves markets, including commercial, industrial, automotive, medical, aerospace, defense, and others.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.